TuHURA Biosciences, Inc. operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms. The company owns and develops a product portfolio of cellular and gene therapies that can detect, monitor, and control cancer. It offers ImmuneFx, a cancer vaccine; Morphogenesis Allograft Tissue with Compatible HLA (MATCH) stem cell banks; Polymer Antibody Cell Separation System (PACS), a device that captures and releases viable targeted cells from large volumes; and BlueBio, a program for mining microbial compounds from the ocean floor. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December, 2023. TuHURA Biosciences, Inc. was incorporated in 1993 and is based in Tampa, Florida.TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc. .